The Effect of Triphala Lavender Tablets on the Treatment of Children with Attention Deficit/Hyperactivity Disorder

Document Type : Original Article (s)

Authors

1 Associate Professor, Department of Psychology, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran

2 Research Center for Biochemistry and Nutrition in Metabolic Diseases, Kashan University of Medical Sciences, Kashan, Iran

3 Student of Medicine, Student Research Committee, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran

Abstract

Background: Attention deficit/hyperactivity disorder (ADHD) is a common psychiatric disorder in the children. The purpose of this study was to evaluate the efficacy of Triphala Lavender tablets as an adjuvant therapy along with methylphenidate on the treatment of children with attention deficit/hyperactivity disorder.Methods: In this clinical trial study that was done in Isfahan Province, Iran, in 2016, 44 children with attention deficit/hyperactivity disorder were enrolled according to inclusion (aged between 6 to 12 years) and exclusion (failure to follow up) criteria. The patients were randomly divided into two group as intervention (treated with methylphenidate and Triphala lavender tablets) and placebo (treated with methylphenidate and placebo). Patients were treated for 8 weeks. The assessment tool was Attention Deficit/Hyperactivity Disorder Rating Scale-IV (ADHD-RS-IV), which was used at the onset, and 2, 4, and 8 weeks after the intervention.Findings: The ADHD-RS-IV scores significantly decreased in both groups after intervention (P < 0.001 for both). In addition, the ADHD-RS-IV in the intervention group was significantly lower than placebo group at the 4th week after the intervention (P = 0.042); but there was no significant difference between the two groups in ADHD-RS-IV at onset, and 2 and 8 weeks after the intervention (P > 0.050 for all).Conclusion: The use of Triphala Lavender tablets as an adjuvant therapy may be effective in patients with attention deficit/hyperactivity disorder, but due to limited study about the role of Triphala Lavender tablets in treatment of these patients, we need future studies with larger sample sizes and longer time.

Keywords

References

  1. Faraone SV, Sergeant J, Gillberg C, Biederman J. The worldwide prevalence of ADHD: is it an American condition? World Psychiatry 2003; 2(2): 104-13.
  2. Balint S, Czobor P, Meszaros A, Simon V, Bitter I. Neuropsychological impairments in adult attention deficit hyperactivity disorder: a literature review. Psychiatr Hung 2008; 23(5): 324-35. [In Hungarian].
  3. Russell V, Allie S, Wiggins T. Increased noradrenergic activity in prefrontal cortex slices of an animal model for attention-deficit hyperactivity disorder--the spontaneously hypertensive rat. Behav Brain Res 2000; 117(1-2): 69-74.
  4. Matza LS, Paramore C, Prasad M. A review of the economic burden of ADHD. Cost Eff Resour Alloc 2005; 3: 5.
  5. Pelham WE, Foster EM, Robb JA. The economic impact of attention-deficit/hyperactivity disorder in children and adolescents. J Pediatr Psychol 2007; 32(6): 711-27.
  6. Swanson JM, Sergeant JA, Taylor E, Sonuga-Barke EJ, Jensen PS, Cantwell DP. Attention-deficit hyperactivity disorder and hyperkinetic disorder. Lancet 1998; 351(9100): 429-33.
  7. Greenhill LL, Posner K, Vaughan BS, Kratochvil CJ. Attention deficit hyperactivity disorder in preschool children. Child Adolesc Psychiatr Clin N Am 2008; 17(2): 347-66, ix.
  8. Faraone SV, Biederman J, Spencer TJ, Aleardi M. Comparing the efficacy of medications for ADHD using meta-analysis. MedGenMed 2006; 8(4): 4.
  9. Faraone SV. Using meta-analysis to compare the efficacy of medications for attention-deficit/hyperactivity disorder in youths. P T 2009; 34(12): 678-94.
  10. Faraone SV, Glatt SJ. A comparison of the efficacy of medications for adult attention-deficit/hyperactivity disorder using meta-analysis of effect sizes. J Clin Psychiatry 2010; 71(6): 754-63.
  11. Harpin VA. Medication options when treating children and adolescents with ADHD: interpreting the NICE guidance 2006. Arch Dis Child Educ Pract Ed 2008; 93(2): 58-65.
  12. Wigal SB. Efficacy and safety limitations of attention-deficit hyperactivity disorder pharmacotherapy in children and adults. CNS Drugs 2009; 23(Suppl 1): 21-31.
  13. Sinha D, Efron D. Complementary and alternative medicine use in children with attention deficit hyperactivity disorder. J Paediatr Child Health 2005; 41(1-2): 23-6.
  14. Pellow J, Solomon EM, Barnard CN. Complementary and alternative medical therapies for children with attention-deficit/hyperactivity disorder (ADHD). Altern Med Rev 2011; 16(4): 323-37.
  15. Akhondzadeh S, Kashani L, Fotouhi A, Jarvandi S, Mobaseri M, Moin M, et al. Comparison of Lavandula angustifolia Mill. tincture and imipramine in the treatment of mild to moderate depression: a double-blind, randomized trial. Prog Neuropsychopharmacol Biol Psychiatry 2003; 27(1): 123-7.
  16. Denner SS. Lavandula angustifolia Miller: English lavender. Holist Nurs Pract 2009; 23(1): 57-64.
  17. Aghili Khorasani MH. Qrabadyan-e Kabir. Tehran, Iran: Research Institute for Islamic and Complementary Medicine; 2007. [In Persian].
  18. Shang CY, Pan YL, Lin HY, Huang LW, Gau SS. An open-label, randomized trial of methylphenidate and atomoxetine treatment in children with attention-deficit/hyperactivity disorder. J Child Adolesc Psychopharmacol 2015; 25(7): 566-73.
  19. Nikfarjam M, Parvin N, Asarzadegan N. The effect of Lavandula angustifolia in the treatment of mild to moderate depression. J Shahrekord Univ Med Sci 2010; 11(4): 66-73. [In Persian].
  20. Kasper S. An orally administered lavandula oil preparation (Silexan) for anxiety disorder and related conditions: an evidence based review. Int J Psychiatry Clin Pract 2013; 17 Suppl 1: 15-22.
  21. Koulivand PH, Khaleghi GM, Gorji A. Lavender and the nervous system. Evid Based Complement Alternat Med 2013; 2013: 681304.
Journal of Isfahan Medical School
Volume 36, Issue 466 - Serial Number 466
January and February 2018
Pages 42-48

Files

History

  • Receive Date: 13 September 2017
  • Revise Date: 01 November 2024
  • Accept Date: 06 April 2022

Share

How to cite

Statistics